AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

ORal Aminaphtone and Combined LidocainE

Recruitingn/aAges 18 Years - 85 YearsAllTreviso Regional Hospital
💬

In plain words

What the trial is, and whether it could suit you

This observational study, called ORACLE (ORal Aminaphtone and Combined LidocainE), is being conducted at Treviso Regional Hospital (Italy) to evaluate the effectiveness of a first-line treatment for patients with internal hemorrhoidal disease (HD). The study focuses on a combination therapy using an oral drug, aminaphtone (Capillarema®), and a topical cream with lidocaine (Octosedan®), compared to standard conservative care. Hemorrhoidal disease is a common condition that can cause bleeding, discomfort, itching, and swelling in the anal area. Many patients experience symptoms that affect their quality of life, even when using standard treatments like fiber supplements and emollient creams. This study involves two groups of patients: * One group will receive oral aminaphtone (Capillarema®) plus lidocaine cream (Octosedan®). * The other group will receive standard advice on diet and hyd

Sign in to get the eligibility rules as simple questions to take to your doctor.

📋 Eligibility rules (as published)
Inclusion Criteria: * Adults aged 18 to 85 years * Diagnosis of symptomatic internal hemorrhoidal disease (Grade I-IV, Goligher classification) * First outpatient consultation for current symptoms * Written informed consent provided Exclusion Criteria: * Active proctologic conditions (e.g., anal fissures, fistulas, condylomas, neoplasms) * Inflammatory bowel disease (IBD) * Known HIV infection * Previous surgical treatment for hemorrhoidal disease (except outpatient procedures performed \>6 months prior) * Current use of psychotropic, antibiotic, antifungal, immunomodulatory, or corticosteroid drugs * Known hypersensitivity to Capillarema® or Octosedan® components
💊

What it tests

  • Not listed
📍

Where

1 site
Regional Hospital Treviso
Treviso, Italy
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy